RSVpreF vaccine

Phase 3

Pfizer

RSVpreF vaccine is one of 4 therapeutic programs targeting Respiratory Syncytial Virus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Respiratory Syncytial VirusCompleted

Respiratory Syncytial VirusPhase 3

Completed

Competition

Competitive Landscape

21 competitors in Respiratory Syncytial Virus

#DrugCompanyPhaseTrials

Placebp

Pfizer

Phase 3

1 2

RSVpreF vaccine

Pfizer

Phase 3

1 3

Mrna-1345

Moderna

Phase 1

3 4

Nimenrix

GSK

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PREGNANT PARTICIPANTS LIVING WITH HIV AND THEIR INFANTS

Completed· Pfizer logo

Pfizer·Phase 3·NCT06325657·681 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RSVpreF vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for RSVpreF vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Pfizer

RSVpreF vaccine

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

References

Drug Info

Quick Facts

Related News